|
nasdaq:cbio
|
43979
|
Apr 14th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 13th, 2024 10:45PM
|
Apr 14th, 2024 10:43AM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 13th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 12th, 2024 10:36PM
|
Apr 13th, 2024 11:11AM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 12th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 11th, 2024 10:40PM
|
Apr 12th, 2024 08:06AM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 11th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 10th, 2024 11:10PM
|
Apr 11th, 2024 10:50AM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 10th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 9th, 2024 10:43PM
|
Apr 10th, 2024 04:59PM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 9th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 8th, 2024 10:54PM
|
Apr 9th, 2024 09:40AM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 8th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 7th, 2024 11:20PM
|
Apr 8th, 2024 06:38PM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 7th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 6th, 2024 10:51PM
|
Apr 6th, 2024 10:51PM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 6th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 5th, 2024 10:51PM
|
Apr 5th, 2024 10:51PM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|
|
nasdaq:cbio
|
43979
|
Apr 5th, 2024 12:00AM
|
Catalyst Biosciences
|
7.0K
|
16.00
|
Open
|
|
Apr 4th, 2024 11:14PM
|
Apr 4th, 2024 11:14PM
|
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
|
Open
|
Protease engineering and proteases in hemostasis
|
Open
|
611 Gateway Blvd
|
South San Francisco
|
CA
|
US
|
94080
|
|
Catalyst Biosciences
|
|
|